LONDON, April 25 (Reuters) - Britain’s Shire Plc said on Friday that 2008 sales of its biggest drug hope, Vyvanse for attention deficit hyperactivity disorder (ADHD), would be at the lower end of its expectations, hitting its shares.
LONDON, April 25 (Reuters) - Britain’s Shire Plc said on Friday that 2008 sales of its biggest drug hope, Vyvanse for attention deficit hyperactivity disorder (ADHD), would be at the lower end of its expectations, hitting its shares.
